84 phenotypes from 6 alleles in 8 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Pnpla2tm1.1Hsul/Pnpla2tm1.1Hsul Tg(Fabp4-cre)1Rev/0 involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL	abnormal adipose tissue physiology	J:176083
	abnormal brown adipose tissue morphology	J:176083
	abnormal oxygen consumption	J:176083
	decreased adipocyte glucose uptake	J:176083
	decreased circulating glucose level	J:176083
	decreased circulating insulin level	J:176083
	decreased fatty acid oxidation	J:176083
	decreased oxygen consumption	J:176083
	impaired adaptive thermogenesis	J:176083
	impaired lipolysis	J:176083
	increased brown adipose tissue amount	J:176083
	increased brown fat cell size	J:176083
	increased gonadal fat pad weight	J:176083
	increased inguinal fat pad weight	J:176083
	increased insulin sensitivity	J:176083
	increased renal fat pad weight	J:176083
	increased susceptibility to diet-induced obesity	J:176083
	increased susceptibility to weight gain	J:176083
	increased total fat pad weight	J:176083
	increased white fat cell size	J:176083
Pnpla2tm1Eek/Pnpla2tm1Eek Tg(Ckmm-cre)5Khn/0 involves: 129S * FVB/N	increased cardiac muscle triglyceride level	J:176252
	increased heart weight	J:176252
Pnpla2tm1Eek/Pnpla2tm1Eek Tg(Myog-cre)1Eno/0 involves: 129S * C57BL/6	abnormal lipid level	J:207007
	increased fatty acids level	J:207007
	increased skeletal muscle triglyceride level	J:207007
Pnpla2tm1Gam/Pnpla2tm1Gam Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA	abnormal cholangiocyte morphology	J:185116
	abnormal hepatocyte morphology	J:185116
	decreased basal metabolism	J:185116
	decreased fatty acid oxidation	J:185116
	increased circulating alanine transaminase level	J:185116
	increased circulating free fatty acids level	J:185116
	increased liver triglyceride level	J:185116
	increased liver weight	J:185116
	macrovesicular hepatic steatosis	J:185116
	microvesicular hepatic steatosis	J:185116
Pnpla2tm1Rze/Pnpla2tm1Rze involves: 129P2/OlaHsd	abnormal cardiovascular system morphology	J:176252
	abnormal enzyme/coenzyme activity	J:160725
	abnormal heart ventricle morphology	J:176252
	abnormal lipid homeostasis	J:160725
	abnormal metabolism	J:176252
	abnormal myocardial fiber mitochondrial morphology	J:176252
	abnormal myocardial fiber morphology	J:176252
	abnormal myocardial fiber physiology	J:176252
	abnormal respiratory quotient	J:176252
	cardiac hypertrophy	J:176252
	decreased circulating free fatty acids level	J:176252
	decreased circulating triglyceride level	J:176252
	decreased oxygen consumption	J:176252
	decreased ventricle muscle contractility	J:176252
	impaired lipolysis	J:160725
	increased brown adipose tissue amount	J:176252
	increased cardiac muscle glycogen level	J:176252
	increased fatty acids level	J:176252
	increased heart left ventricle weight	J:176252
	increased heart rate	J:176252
	increased liver triglyceride level	J:160725, J:176252
	increased respiratory quotient	J:176252
	increased triglyceride level	J:160725, J:176252
	increased white adipose tissue amount	J:176252
	normal integument phenotype	J:160725
	premature death	J:176252
	thick interventricular septum	J:176252
Pnpla2tm1Rze/Pnpla2tm1Rze involves: 129P2/OlaHsd * C57BL/6	abnormal brown adipose tissue morphology	J:108546
	abnormal cardiomyocyte apoptosis	J:108546
	abnormal cardiovascular system physiology	J:108546
	abnormal circulating glucose level	J:108546
	abnormal circulating hormone level	J:108546
	abnormal circulating insulin level	J:108546
	abnormal gas homeostasis	J:108546
	abnormal glucose tolerance	J:108546
	abnormal heart morphology	J:108546
	abnormal homeostasis	J:108546
	abnormal lipid homeostasis	J:108546
	abnormal myocardial fiber morphology	J:108546
	abnormal myocardium layer morphology	J:108546
	abnormal respiratory quotient	J:108546
	abnormal white adipose tissue morphology	J:108546
	cardiac edema	J:108546
	cardiac fibrosis	J:108546
	congestive heart failure	J:108546
	decreased circulating free fatty acids level	J:108546
	decreased circulating glucose level	J:108546
	decreased circulating HDL cholesterol level	J:108546
	decreased circulating insulin level	J:108546
	decreased circulating triglyceride level	J:108546
	decreased circulating VLDL triglyceride level	J:108546
	decreased oxygen consumption	J:108546
	decreased ventricle muscle contractility	J:108546
	dilated heart left ventricle	J:108546
	dilated heart right ventricle	J:108546
	hepatic steatosis	J:108546
	impaired adaptive thermogenesis	J:108546
	impaired lipolysis	J:108546
	improved glucose tolerance	J:108546
	increased body mass index	J:108546
	increased body weight	J:108546
	increased brown adipose tissue amount	J:108546
	increased cardiac muscle triglyceride level	J:108546
	increased circulating leptin level	J:108546
	increased gonadal fat pad weight	J:108546
	increased heart weight	J:108546
	increased inguinal fat pad weight	J:108546
	increased insulin sensitivity	J:108546
	increased interscapular fat pad weight	J:108546
	increased liver triglyceride level	J:108546
	increased triglyceride level	J:108546
	premature death	J:108546
	pulmonary vascular congestion	J:108546
	thick interventricular septum	J:108546
Pnpla2tm1Rze/Pnpla2tm1Rze Tg(Myh6-Pnpla2)94Biat/0 involves: 129P2/OlaHsd * C57BL/6 * DBA/2	normal cardiovascular system phenotype	J:176252
	decreased circulating free fatty acids level	J:176252
	decreased circulating triglyceride level	J:176252
	increased brown adipose tissue amount	J:176252
	increased white adipose tissue amount	J:176252
	normal mortality/aging	J:176252
Tg(Ckm-Pnpla2)164Eek/0 involves: FVB/N	decreased skeletal muscle triglyceride level	J:207007